Q3 Interim report – Launch in US with own CLIA laboratory
SEK 000sQ321/22Q320/21May-Jan 21/22May-Jan 20/21Full year20/21Net sales3141,3769631,7592,077Operating profit (loss)-14,417-11,062-40,970-28,012-40,181Profit (loss) for the period-14,334-10,909-40,947-27,491-39,482Earnings per share, after dilution-0.50-0.38-1.44-0.97-1.39Significant events during the third quarter Article on the DiviTum®TKa Budget Impact Model published in the Journal of Medical Economics.Three studies with DiviTum®TKa presented at SABCS 2021.Start of TK IMPACT study at Washington University in St. Louis.Significant events after the end [...]